Enabling Science at Scale
Danaher’s William Blake, Chief Technology Officer, Human-Based R&D, pens this piece on how bringing rigorous engineering processes into the earliest stages of drug discovery could drastically lower the current attrition rate.
A feature section on Molecular Devices touches on how the company’s AI-powered analytics, Organoid Innovation Center, and organoid expansion services are just some of the technologies supporting the adoption of engineering biology.